Michael Jain

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

Michael Jain

Sep 14, 2024, 17:46 | Insight

Kai Rejeski: Second Primary Malignancies following CAR T-cell therapy

Kai Rejeski shared a post on X about a recent paper by Tobias Tix et…

Aug 4, 2024, 09:41 | Insight

Michael Jain: 5-year outcomes of standard-of-care Axicabtagene Ciloleucel in lymphoma patients

Michael Jain, Oncologist at Moffitt Cancer Center, shared on X: "What is important for long-term…

Apr 2, 2024, 05:25 | Blog

Marco Davila: Had a great time hosting Michael Jain to give a powerhouse Medicine Grand Rounds at Roswell Park

Marco Davila, SVP and Associate Cancer Center Director of Translational Research at Roswell Park Comprehensive…

Dec 11, 2023, 17:59 | Blog

Khushali Jhaveri: Our work highlights the crucial role of muscle health pre and post treatment CART

Khushali Jhaveri, Haematology-Oncology Fellow at Moffitt Cancer Centre, shared on X/Twitter: “Excited to present our…

All: 4 Posts: 1 - 100

'

Dr. Manette Le Grange joins OncoDaily Editorial Board

'

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

'

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

'

Highlights from TTLC2025

'

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Special Coverage

ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023